323 related articles for article (PubMed ID: 34281838)
1. Cetyltrimethylammonium Bromide Attenuates the Mesenchymal Characteristics of Hypopharyngeal Squamous Cell Carcinoma Through Inhibiting the EGFR/PI3K/AKT Signaling Pathway.
Wu TK; Ou YC; Chen YP; Huang FM; Pan YR; Lee CJ
Anticancer Res; 2021 Aug; 41(8):3789-3799. PubMed ID: 34281838
[TBL] [Abstract][Full Text] [Related]
2. Cetyltrimethylammonium Bromide Disrupts the Mesenchymal Characteristics of HA22T/VGH Cells
Yue CH; Chen CH; Lee WT; Su TF; Pan YR; Chen YP; Huang FM; Lee CJ
Anticancer Res; 2020 Aug; 40(8):4513-4522. PubMed ID: 32727781
[TBL] [Abstract][Full Text] [Related]
3. Cetrimonium Bromide Inhibits Cell Migration and Invasion of Human Hepatic SK-HEP-1 Cells Through Modulating the Canonical and Non-canonical TGF-β Signaling Pathways.
Wu TK; Chen CH; Pan YR; Hu CW; Huang FM; Liu JY; Lee CJ
Anticancer Res; 2019 Jul; 39(7):3621-3631. PubMed ID: 31262888
[TBL] [Abstract][Full Text] [Related]
4. Cetyltrimethylammonium Bromide Suppresses the Migration and Invasion of Hepatic Mahlavu Cells by Modulating Fibroblast Growth Factor Signaling.
Wu TK; Chen CH; Lee WT; Su TF; Pan YR; Huang FM; Lee CJ
Anticancer Res; 2020 Sep; 40(9):5059-5069. PubMed ID: 32878794
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of radiation induced migration of human head and neck squamous cell carcinoma cells by blocking of EGF receptor pathways.
Pickhard AC; Margraf J; Knopf A; Stark T; Piontek G; Beck C; Boulesteix AL; Scherer EQ; Pigorsch S; Schlegel J; Arnold W; Reiter R
BMC Cancer; 2011 Sep; 11():388. PubMed ID: 21896192
[TBL] [Abstract][Full Text] [Related]
6. Cetyltrimethylammonium Bromide Disrupts Mesenchymal Characteristics of Human Tongue Squamous Cell Carcinoma SCC4 Cells Through Modulating Canonical TGF-β/Smad/miR-181b/TIMP3 Signaling Pathway.
Yue CH; Chen CH; Pan YR; Chen YP; Huang FM; Lee CJ
Anticancer Res; 2021 Dec; 41(12):6095-6104. PubMed ID: 34848464
[TBL] [Abstract][Full Text] [Related]
7. Campothecin suppresses cell proliferation and migration in head and neck squamous cell carcinoma by blocking RAB27A-mediated phosphatidylinositol 3 kinase (PI3K)/protein kinase B (AKT) pathway.
Zhao Y; Wang Y; Zhao L; Qu L; Zheng JH
J Physiol Pharmacol; 2024 Apr; 75(2):205-213. PubMed ID: 38736267
[TBL] [Abstract][Full Text] [Related]
8. The PI3K/Akt/mTORC signaling axis in head and neck squamous cell carcinoma: Possibilities for therapeutic interventions either as single agents or in combination with conventional therapies.
Akbari Dilmaghani N; Safaroghli-Azar A; Pourbagheri-Sigaroodi A; Bashash D
IUBMB Life; 2021 Apr; 73(4):618-642. PubMed ID: 33476088
[TBL] [Abstract][Full Text] [Related]
9. CSC-3436 inhibits TWIST-induced epithelial-mesenchymal transition via the suppression of Twist/Bmi1/Akt pathway in head and neck squamous cell carcinoma.
Lai YJ; Yu WN; Kuo SC; Ho CT; Hung CM; Way TD; Chen CT
J Cell Physiol; 2019 Jun; 234(6):9118-9129. PubMed ID: 30341909
[TBL] [Abstract][Full Text] [Related]
10. Nicotine promotes lymph node metastasis and cetuximab resistance in head and neck squamous cell carcinoma.
Shimizu R; Ibaragi S; Eguchi T; Kuwajima D; Kodama S; Nishioka T; Okui T; Obata K; Takabatake K; Kawai H; Ono K; Okamoto K; Nagatsuka H; Sasaki A
Int J Oncol; 2019 Jan; 54(1):283-294. PubMed ID: 30431077
[TBL] [Abstract][Full Text] [Related]
11. Scutellarin inhibits the invasive potential of malignant melanoma cells through the suppression epithelial-mesenchymal transition and angiogenesis via the PI3K/Akt/mTOR signaling pathway.
Li CY; Wang Q; Wang X; Li G; Shen S; Wei X
Eur J Pharmacol; 2019 Sep; 858():172463. PubMed ID: 31211986
[TBL] [Abstract][Full Text] [Related]
12. RhoC mediates epidermal growth factor-stimulated migration and invasion in head and neck squamous cell carcinoma.
Tumur Z; Katebzadeh S; Guerra C; Bhushan L; Alkam T; Henson BS
Neoplasia; 2015 Jan; 17(1):141-51. PubMed ID: 25622907
[TBL] [Abstract][Full Text] [Related]
13. Targeting EGFR-PI3K-AKT-mTOR signaling enhances radiosensitivity in head and neck squamous cell carcinoma.
Horn D; Hess J; Freier K; Hoffmann J; Freudlsperger C
Expert Opin Ther Targets; 2015 Jun; 19(6):795-805. PubMed ID: 25652792
[TBL] [Abstract][Full Text] [Related]
14. Targeting mTOR-CCL20 Signaling May Improve Response to Docetaxel in Head and Neck Squamous Cell Carcinoma.
Chou MH; Chuang HC; Lin YT; Tsai MH; Kao YH; Lin IC; Huang TL; Fang FM; Chien CY
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33802643
[TBL] [Abstract][Full Text] [Related]
15. Antimetastatic Effects of Sesamin on Human Head and Neck Squamous Cell Carcinoma through Regulation of Matrix Metalloproteinase-2.
Chen JM; Chen PY; Lin CC; Hsieh MC; Lin JT
Molecules; 2020 May; 25(9):. PubMed ID: 32397656
[TBL] [Abstract][Full Text] [Related]
16. DKK3 knockdown confers negative effects on the malignant potency of head and neck squamous cell carcinoma cells via the PI3K/Akt and MAPK signaling pathways.
Katase N; Nishimatsu SI; Yamauchi A; Yamamura M; Fujita S
Int J Oncol; 2019 Mar; 54(3):1021-1032. PubMed ID: 30569110
[TBL] [Abstract][Full Text] [Related]
17. Activation of EGFR promotes squamous carcinoma SCC10A cell migration and invasion via inducing EMT-like phenotype change and MMP-9-mediated degradation of E-cadherin.
Zuo JH; Zhu W; Li MY; Li XH; Yi H; Zeng GQ; Wan XX; He QY; Li JH; Qu JQ; Chen Y; Xiao ZQ
J Cell Biochem; 2011 Sep; 112(9):2508-17. PubMed ID: 21557297
[TBL] [Abstract][Full Text] [Related]
18. APLNR is involved in ATRA-induced growth inhibition of nasopharyngeal carcinoma and may suppress EMT through PI3K-Akt-mTOR signaling.
Liu Y; Liu Q; Chen S; Liu Y; Huang Y; Chen P; Li X; Gao G; Xu K; Fan S; Zeng Z; Xiong W; Tan M; Li G; Zhang W
FASEB J; 2019 Nov; 33(11):11959-11972. PubMed ID: 31408612
[TBL] [Abstract][Full Text] [Related]
19. G-Protein-Coupled Receptor Kinase-Interacting Protein 1 (GIT1) Promotes Head and Neck Squamous Cell Carcinoma Metastases via Activating the PI3K/AKT/mTOR Signal Pathway.
Xu R; Xu R; Wang Y; Wang W; Jiang L; Gong S
Comput Math Methods Med; 2022; 2022():6881932. PubMed ID: 35116073
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of invasion and migration by newly synthesized quinazolinone MJ-29 in human oral cancer CAL 27 cells through suppression of MMP-2/9 expression and combined down-regulation of MAPK and AKT signaling.
Lu CC; Yang JS; Chiang JH; Hour MJ; Amagaya S; Lu KW; Lin JP; Tang NY; Lee TH; Chung JG
Anticancer Res; 2012 Jul; 32(7):2895-903. PubMed ID: 22753753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
